Drug Type Small molecule drug |
Synonyms Ulodesine (USAN), Ulodesine succinate + [5] |
Target |
Mechanism PNP inhibitors(Purine nucleoside phosphorylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization Laevoroc Oncology AGStartup |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC12H16N4O3 |
InChIKeyAFNHHLILYQEHKK-BDAKNGLRSA-N |
CAS Registry548486-59-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Preclinical | CH | Laevoroc Oncology AGStartup | 14 Dec 2022 |
Hyperuricemia | Preclinical | US | 01 Dec 2010 | |
Gout | Preclinical | US | 01 Sep 2009 | |
Psoriasis | Preclinical | US | 01 Jul 2007 |
Not Applicable | 278 | rxxouwwvkd(ydbogkjnnv) = ulljpzbdwg ophnafoahb (scvjygwkcp ) View more | - | 06 Jun 2012 | |||
Placebo | rxxouwwvkd(ydbogkjnnv) = twonzbckbr ophnafoahb (scvjygwkcp ) View more | ||||||
Not Applicable | Gout sUA | PNP | 87 | kpvxujmpzs(fguvzewpek) = pwyfapzipv jtavfgwfob (dotpqfmgos ) | Positive | 25 May 2011 | ||
kpvxujmpzs(fguvzewpek) = wxnhptngcs jtavfgwfob (dotpqfmgos ) |